Pfizer Ends Pact With GlycoMimetics After SCD Failure

Rivipansel’s Sickle Cell Disease Trial Failure Triggered Pfizer’s Move

 
• By Sten Stovall
Contract_Termination
GlycoMimetics To Decide Whether Or Not To Continue Rivipansel Program • Source: Shutterstock

More from Business

More from Scrip